Skip to content

Non-invasive Ventilation Assisted Fiber-optic Bronchoscopy

Efficacy and Safety of Using Non-invasive Ventilation Assisted Fiber-optic Bronchoscopy

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06115395
Enrollment
100
Registered
2023-11-03
Start date
2020-07-25
Completion date
2025-12-31
Last updated
2025-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases, Lung

Keywords

non- invasive ventilation, fiber-optic bronchoscopy.

Brief summary

The purpose of this study is the evaluation of using bi-level positive airway pressure ventilation in candidates for fiber-optic bronchoscopy regarding benefits and drawbacks.

Detailed description

In this study patients who will be candidate for fiber-optic bronchoscopy for diagnostic or therapeutic reasons will be evaluated by the Chest Medicine Department, Mansoura University Hospitals. All patients will be subjected to full history taking, full examination, routine laboratory investigations, arterial blood gases (ABG), chest X-ray, chest computed tomography (CT). Non-invasive ventilation: Group 1 (hypoexemic patient who will undergo bronchoscopy under non- invasive ventilation{NIV}) will be on NIV half an hour prior and throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria, Group 2 (hypoxemic patients who will undergo conventional bronchoscopy ) will be on conventional oxygen therapy half an hour prior and throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria, Group 3 (non- hypoxemic patients who will undergo conventional bronchoscopy ) will be on NIV throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria, Group 4 (non- hypoxemic patients who will undergo conventional bronchoscopy) will be on conventional oxygen therapy throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria.

Interventions

DEVICEnon- invasive ventilator

Group 1 (hypoexemic patient who will undergo bronchoscopy under non- invasive ventilation{NIV} and conventional o2 therapy) will be on NIV half an hour prior and throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria

DEVICEfiber-optic bronchoscopy

Group 2 (hypoxemic patients who will undergo conventional bronchoscopy under conventional o2 therapy without NIV ) will be on conventional oxygen therapy half an hour prior and throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)

Masking description

Sample method: Method of randomization was stratified random sampling method was adopted to create matched study groups. Patients admitted for bronchoscopy were classified into two categories: 1. A) Non hypoxemic group. 2. B) Hypoxemic group. 3. From each category: 50 patients were selected and allocated randomly in the study groups (either intervention or control group) using lottery method. So, each study group with included 25 patients from each category forming a total of 50 patients in each studies categories.

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patients who admitted to the pulmonology ward or intensive care unit with any (diagnostic and/or therapeutic) bronchoscopy indication. 1. Age 18 years or more. 2. Patients accepted to participate in the study.

Exclusion criteria

* Patients with: 1. Cardiac or respiratory arrest. 2. Impaired consciousness or confusion. 3. Type II respiratory failure. 4. Hemodynamic instability. 5. Inability to cooperate or to protect the airway. 6. Vomiting, bowel obstruction, recent upper gastrointestinal tract surgery and esophageal injury. 7. Patients refusing participation in the study. 8. Patients unfit for NIV and or NIV mask. 9. Intubation and or invasive ventilation candidates. 10. Presence of contraindications for bronchoscopy procedure such as insufficient platelet number or coagulopathy.

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of the changes in oxygen saturation, heart rate, respiratory rate, blood pressure, dyspnea score and arterial blood gases in bronchoscopy procedure4 yearsEvaluate changes and when to reach base line in each of 1- (SPO2) by pulse oximeter in (percentage %) at base line, 15 minute before, during and immediately after bronchoscopy. 2-heart rate in (beat/minute) at base line, 15 minute before, during and immediately after bronchoscopy. 3-respiratory rate in (cycle/minute) at base line, 15 minute before, during and immediately after bronchoscopy. 4-mean arterial blood pressure in {millimeter/mercury mm/Hg)} at base line, 15 minute before, during and immediately after bronchoscopy. 5-dyspnea score in {grade 0-3 according to: (mMRC)} 15 minute before and immediately after bronchoscopy. arterial blood gases (PH, Paco2 in {millimeter/mercury (mm/Hg)}, Pao2 in {millimeter/mercury (mm/Hg)},Spo2 (percentage %) andHco3 in {millimol (mmol/l)} before and after bronchoscopy. To show effects of using NIV and conventional o2 therapy and using of conventional o2 therapy alone on these parameters in the studied patients in bronchoscopy.

Secondary

MeasureTime frameDescription
Fiber-optic bronchoscopy complications4 yearsThe need for intubation, if it occurs within two to eight hours of bronchoscopy, it was considered as a complication possibly related to bronchoscopy. This time span was adopted from previous studies (Hilbertet et al., 2001). Also the existence of complications as hemorrhage, pneumothorax, hypotension, arrhythmia) that occurred during bronchoscopy and in the first 24 hours following bronchoscopy, which could possibly be related to the procedure (Schönhofer et al., 2008).

Countries

Egypt

Contacts

Primary ContactWalaa Abd El Aziz, MD
Wm22446699@gmail.com01064904172
Backup ContactMohamed Mansour, MD
Mohammedmansour.md@gmail.com01009400754

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026